United Therapeutics | UTHR - Cash And Equivalent


United Therapeutics reported $1.34B in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Amarin USD 122.8M 25.08M Sep/2025
Ardelyx USD 42.72M 47.32M Sep/2025
Baxter International USD 1.97B 240M Dec/2025
Bayer EUR 5.9B 1.34B Sep/2025
BioCryst Pharmaceuticals USD 84.08M 3.95M Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.31B 61.57M Dec/2025
Emergent BioSolutions USD 111.7M 23.9M Dec/2023
Esperion Therapeutics USD 92.45M 6.39M Sep/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Halozyme Therapeutics USD 133.82M 285.84M Dec/2025
Insmed USD 510.44M 175.68M Dec/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Lexicon Pharmaceuticals USD 21.36M 41.52M Jun/2025
Moderna USD 2.6B 1.46B Dec/2025
Omeros USD 1.9M 2.36M Jun/2025
Pfizer USD 1.34B 295M Sep/2025
PTC Therapeutics USD 984.65M 312.03M Dec/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
United Therapeutics USD 1.34B 253M Sep/2025
Vertex Pharmaceuticals USD 6.61B 321.1M Dec/2025